Metabolic Reprogramming and Neurotransmitter Signaling Co-Option in the Glioma Immune Microenvironment: Dual-Axis Regulation of Immunosuppression
Biomolecules · 28.06.2026 · 16 (7) · 956
DOI: 10.3390/biom16070956 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 28.06.2026. Verfasst von Pengyu Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Techn…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Neurotransmitter Agents, Glioma, Brain Neoplasms. Die Arbeit nennt 205 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, Medical University of Lodz.
Abstract (Originalsprache)
Glioma, particularly glioblastoma (GBM), is characterized by a strongly immunosuppressive tumor microenvironment that limits durable therapeutic responses. This review examines two interacting regulatory aspects of this microenvironment: metabolic reprogramming and neurotransmitter signaling co-option. Metabolic reprogramming is characterized by Warburg-type aerobic glycolysis, lactate accumulation, nutrient competition, and epigenetic lactylation, which generate an acidic and metabolically restrictive niche that impairs cytotoxic immune populations. In parallel, neurotransmitter signaling co-option, particularly through glutamatergic and GABAergic pathways, can influence neuron–glioma communication, microglial/macrophage phenotypes, and selected lymphocyte functions. As direct evidence for bidirectional interactions between metabolic reprogramming and neurotransmitter signaling in glioma remains incomplete, this relationship is presented as a working neurometabolic framework rather than a fully resolved mechanism. Lactate-driven immunometabolic suppression and glutamatergic neuron–glioma signaling currently have the strongest support from glioma-specific studies, whereas some GABAergic, serotonergic, and macrophage-metabolic mechanisms remain emerging or context-dependent. The review also considers how mechanism-guided patient stratification, metabolically optimized immunotherapy and mechanism-based combination strategies targeting defined metabolic and neurotransmitter pathways may help restore antitumor immune competence within the glioma microenvironment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
- Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, 92-215 Lodz, Poland.
- Department of Bioinorganic Chemistry, Medical University of Lodz, 90-151 Lodz, Poland.
ORCID-Profile: Kamil Saramowicz, Angelika Adamus-Grabicka, Joanna Sikora, Wioletta Rozpędek-Kamińska
Förderung
- Fundamental Research Funds for the Central Universities
- Medical University of Lodz
Zitieren
APA
Zhao, P., Saramowicz, K., Adamus-Grabicka, A., Sikora, J., & Rozpędek-Kamińska, W. (2026). Metabolic Reprogramming and Neurotransmitter Signaling Co-Option in the Glioma Immune Microenvironment: Dual-Axis Regulation of Immunosuppression. Biomolecules, 16(7), 956. https://doi.org/10.3390/biom16070956
Vancouver
Zhao P, Saramowicz K, Adamus-Grabicka A, Sikora J, Rozpędek-Kamińska W. Metabolic Reprogramming and Neurotransmitter Signaling Co-Option in the Glioma Immune Microenvironment: Dual-Axis Regulation of Immunosuppression. Biomolecules. 2026;16(7):956. doi:10.3390/biom16070956
BibTeX
@article{Zhao2026,
author = {Zhao, Pengyu and Saramowicz, Kamil and Adamus-Grabicka, Angelika and Sikora, Joanna and Rozpędek-Kamińska, Wioletta},
title = {Metabolic Reprogramming and Neurotransmitter Signaling Co-Option in the Glioma Immune Microenvironment: Dual-Axis Regulation of Immunosuppression},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {7},
pages = {956},
doi = {10.3390/biom16070956}
}
EUVIMED